8 research outputs found
Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study).
Background: Trastuzumab is widely used as the treatment of choice for HER2-positive metastatic breast cancer
(MBC).
Patients and methods: Seventy patients, median age 57 years and range 31–81 years, were included in our
retrospective analysis with the aim to evaluate safety and activity of trastuzumab-containing therapies.
Results: We observed for first-line treatment response rate (RR) 41%, stable disease (SD) 47% and time to
progression (TTP) 8 months (range 1–44). Corresponding numbers for second line were RR 23%, SD 62% and (TTP) 9
months (range 3–23) and beyond second line RR 22%, SD 78% and (TTP) 9 months (range 4–19). Overall survival was
19.2 months (3–62 months). The median cumulative dose of trastuzumab administrated was 5286 mg
(464–17 940 mg). Trastuzumab was well tolerated. Median left ventricular ejection function (LVEF) at baseline was
62% and at the end of treatment was 59%. The more relevant adverse events consisted of an asymptomatic
decrease in LVEF to 40% (baseline 60%) and a grade 3 symptomatic increase in bilirubin.
Conclusion: Trastuzumab-containing therapies in MBC show a good safety and toxicity profile and a remarkable
activity even in heavily pretreated women. Patients should benefit from continued trastuzumab therapy, as shown
by the maintenance of (TTP) even beyond second-line treatment
Indagine sulla qualitĂ di vita ansia e depressione in un gruppo di pazienti affette da carcinoma mammario
Low dose oral chemotherapy for hormone refractory prostate carcinoma estramustine phosphate versus estramustine phosphate and etoposide. A Randomized phase II study of GSTU foundation
Opioids in advanced cancer: use, storage and disposal in the home
Objectives To determine the patterns of storing, using and disposing of opioids among patients with advanced cancer followed at home. Methods Patients who were prescribed opioids were selected. Prescribed opioids and their doses used for background pain and breakthrough pain were collected, as well as CAGE (cut down, annoyed, guilty and eye opener) for alcohol and drugs, smoking and history of illicit substance use. Questions regarding the opioid use, storage and disposal were posed. Results 100 patients were surveyed. Fifty-one patients had unused opioids at home, 25 patients did not throw away the drugs, 40 patients saved opioids for future use and 35 patients were unaware of proper opioid disposal methods. A total of 28 patients reported unsafe use by sharing or losing their opioids; 12 patients were unaware that their opioid could be fatal when taken by others. Most patients acknowledged that pain medications could be dangerous when taken by others. Patients with a partner and who were married were more likely to keep their opioids locked (p=0.028 and p=0.025, respectively). Conclusion A large number of patients with advanced cancer followed at home do not store, use and dispose of opioids safely. Patient education programmes should be incorporated to decrease the availability of opioids at home for abuse, diversion, and accidental poisoning